A better understanding of how cis-acting, long-range regulatory control elements surrounding the human FXN gene, and the trans-acting protein factors that act upon them, are responsible for gene expression in healthy and affected individuals, has the potential to lead to the development of new strategies that target the upregulation of the FXN gene as a therapy for FRDA [17]. Here, FXN is linked to Friedreich ataxia.